Medical aesthetics company JETEMA is stepping up its push into the U.S. beauty and plastic surgery market.
JETEMA said on the 17th that its U.S. subsidiary, JETEMA USA, recently signed a product supply agreement with Hanmi Pharmaceutical for a business partnership in the U.S. beauty and plastic surgery market.
Earlier, the two companies signed a memorandum of understanding (MOU) in September for the joint development of beauty and plastic surgery products in the United States and a comprehensive business partnership. The company said the new contract is the first concrete achievement of the collaboration agreed to at that time.
Under the agreement, Hanmi Pharmaceutical will handle the development, manufacturing and supply of beauty and plastic surgery pharmaceuticals and medical devices. JETEMA secured the right to import, store, sell and distribute in the United States—the contract territory—products supplied by Hanmi Pharmaceutical, applying its own brand and trademarks.
JETEMA expects the deal to serve as a springboard to fully build out and expand its local U.S. distribution and marketing systems. A JETEMA official said, "This supply agreement is the first fruit of the comprehensive business partnership the two companies signed with the goal of entering the U.S. beauty and plastic surgery market," adding, "By enabling us to distribute and sell products under our own brand, it will further strengthen JETEMA's business base in the U.S. market."
The official added, "Through this cooperation, we will solidify JETEMA's position in the United States, and JETEMA USA, established in 2022 and leading the clinical trials and development of botulinum toxin in the United States, will gain an important foothold to expand local sales."
Starting with this agreement, the two companies plan to continue discussions on additional product lines and business scopes where further collaboration is possible.